Imago BioSciences to Host Virtual Investor Event
Imago BioSciences announced a virtual investor event on June 11, following its presentations at the 2022 European Hematology Association (EHA) Congress on June 10. The event will showcase updated data from two Phase 2 studies of bomedemstat for treating Essential Thrombocythemia and Myelofibrosis. Interested parties can join via phone or webcast. The company has received multiple designations for bomedemstat from the FDA and EMA, indicating its potential significance in treating these blood disorders.
- None.
- None.
- Company to host virtual investor event on Saturday, June 11 at 10:30 AM ET following its June 10th presentation of updated data from Phase 2 studies of bomedemstat for the treatment of Essential Thrombocythemia and Myelofibrosis at the 2022 European Hematology Association (EHA) Congress -
SOUTH , June 06, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that a virtual investor event will be hosted by the company’s management team following the company’s presentations at EHA in Vienna, Austria and virtually.
Individuals interested in listening to the event at 10:30 a.m. ET on Saturday, June 11 may do so by dialing (844) 348-6880 for domestic callers, or (914) 800-3944 for international callers, and reference conference ID: 3493998; or from the webcast link in the investor relations section of the company's website at: www.imagobio.com. The webcast will be available in the investor relations section on the Company's website for 90 days following the completion of the call.
Imago will present two posters at EHA reporting updated data from its Phase 2 studies of bomedemstat for the treatment of Essential Thrombocythemia and Myelofibrosis, respectively.
The titles of the poster presentations are:
- Poster Presentation Title: “A Phase 2 Study of IMG-7289 (Bomedemstat) in Patients with Advanced Myelofibrosis”
Presentation Date & Time: Friday, June 10, 2022, at 10:30 AM ET
- Poster Presentation Title: “A Phase 2 Study of the LSD1 Inhibitor IMG-7289 (Bomedemstat) for the Treatment of Essential Thrombocythemia (ET)”
Presentation Date & Time: Friday, June 10, 2022, at 10:30 AM ET
The abstracts are available on the EHA meeting website at www.journals.lww.com, as an official supplement of HemaSphere, and can also be accessed through “Events and Presentations” on Imago’s investor relations website.
About Imago BioSciences
Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com, www.etclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.
Forward Looking Statements
This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “may,” “will,” “should,” “expect,” “believe” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.
These statements may relate to, but are not limited to, the results, conduct, progress and timing of Imago clinical trials, the regulatory approval path for bomedemstat, as well as assumptions relating to the foregoing. Forward looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Important factors that could affect future results and cause those results to differ materially from those expressed in the forward-looking statements include: our limited operating history and lack of products for commercial sale; our significant losses since inception and for the foreseeable future; our need for substantial additional financing; our unpredictable operating results; our business’s dependence on development, regulatory approval and commercialization of our product candidates; difficulties in enrolling patients and risks of substantial delays in our clinical trials; our minimal control over product candidates in investigator-initiated clinical trials; uncertainties in the outcomes of our clinical studies; uncertainties in the regulatory review and approval of our product candidates if our pivotal studies are positive; potentially material changes to the interim, top-line and preliminary data from our clinical trials; potential undesirable effects of our product candidates and safety or supply issues with combination-use products; our potential inability to obtain and maintain orphan drug designation and delays in approvals despite Fast Track designation; risks related to clinical trials outside of the United States; our need to manufacture multiple batches of bomedemstat using a commercial current Good Manufacturing Process; risks related to COVID-19 or other pandemics, natural disasters and wars; risks related to competition; difficulties in expanding our organization and managing growth, attracting and retaining senior management and key scientific personnel and establishing sales and other commercialization functions; risks related to information technology system and cybersecurity; risks related to misconduct of our employees and independent contractors; risks related to hazardous materials and our compliance with environmental laws and regulations; risks related to litigation and other claims; risks related to reliance on third parties to conduct and support preclinical studies and clinical trials, and to manufacture our product candidates; risks related to third-party intellectual property infringement claims and our ability to protect our own intellectual property; risks related to governmental policies and regulations including with respect to drug prices and reimbursement, and changes thereof; risks related to our common stock; risks related to our public company, “emerging growth company” and “smaller reporting company” status; risks related to internal control over financial reporting; and other risks and uncertainties, including those listed in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 and our subsequent quarterly reports.
Except as required by law, Imago does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts
INVESTORS
Laurence Watts
Gilmartin Group, LLC.
laurence@gilmartinir.com
MEDIA
Ian Stone
Canale Communications
ian@canalecomm.com
Source: Imago BioSciences
FAQ
What is the date of the Imago BioSciences virtual investor event?
What studies will Imago BioSciences present at the EHA Congress?
How can I access the Imago BioSciences investor event?
What are the titles of the presentations at the EHA Congress?
Does bomedemstat have any designations from regulatory bodies?
